GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nemaura Medical Inc (OTCPK:NMRD) » Definitions » EBIT

Nemaura Medical (Nemaura Medical) EBIT : $-4.98 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Nemaura Medical EBIT?

Nemaura Medical's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-0.24 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.98 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nemaura Medical's annualized ROC % for the quarter that ended in Dec. 2023 was -27.76%. Nemaura Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -48.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nemaura Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -23.57%.


Nemaura Medical EBIT Historical Data

The historical data trend for Nemaura Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nemaura Medical EBIT Chart

Nemaura Medical Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.48 -4.78 -4.59 -7.57 -7.73

Nemaura Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.63 -2.42 -1.95 -0.38 -0.24

Competitive Comparison of Nemaura Medical's EBIT

For the Medical Devices subindustry, Nemaura Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nemaura Medical's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nemaura Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nemaura Medical's EV-to-EBIT falls into.



Nemaura Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nemaura Medical  (OTCPK:NMRD) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nemaura Medical's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-6.164 * ( 1 - 0% )/( (21.77 + 22.64)/ 2 )
=-6.164/22.205
=-27.76 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Nemaura Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.944/( ( (0.582 + max(2.315, 0)) + (0.559 + max(0.465, 0)) )/ 2 )
=-0.944/( ( 2.897 + 1.024 )/ 2 )
=-0.944/1.9605
=-48.15 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 2.911 + 3.281) - (0.515 + 1.129 + 2.233)
=2.315

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 3.672 + 0.146) - (1.153 + 1.184 + 1.016)
=0.465

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nemaura Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-4.984/21.144
=-23.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nemaura Medical EBIT Related Terms

Thank you for viewing the detailed overview of Nemaura Medical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Nemaura Medical (Nemaura Medical) Business Description

Traded in Other Exchanges
N/A
Address
57 West 57th Street, New York, NY, USA, 10019
Nemaura Medical Inc is a medical technology company developing sugarBEAT as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and pre-diabetics to manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading. SugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with an app displaying glucose readings at five-minute intervals for periods up to 24 hours.
Executives
Bashir Timol director, 10 percent owner, officer: Chief Business Officer C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Chowdhury Dewan Fazlul Hoque director, 10 percent owner, officer: CEO & President CHAMWOOD BUILDING, HOLYWELL PARK, ASHBURY ROAD, LOUGHBOROUGH LEICS X0 LE113AQ
Salim Natha director LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF
Justin James Mclarney officer: Chief Financial Officer C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Sufyan Ismail 10 percent owner C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Thomas Peter Moore director C/O NEMAURA MEDICAL, INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Timothy Christopher Johnson director C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Iain Anderson officer: CFO LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF
Kathryn Farrar officer: Director of Finance C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Julie Pomeroy officer: Director of Finance C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Richard Toon officer: Technical & Bus. Dev. Manager C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT